drugset / Trial / NCT01824420

Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

NCT01824420

Phase 4 Completed 129 enrolled Buddhist Tzu Chi General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate if oxybutynin ER adding on antimuscarinics is more effective than mono-antimuscarinic treatment for patients with refractory OAB

Timeline

Start
2013-03
Primary completion
2017-02
Completion
2017-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxybutynin Small molecule 5 mg
Background Tolterodine Small molecule 4 mg

Indications